Business Wire

TOKYO-NIGHT-&-LIGHT-PR

14.8.2024 06:45:35 CEST | Business Wire | Press release

Share
J-Pop Stars Pump up the World’s Largest Projection Mapping Show at the Tokyo Metropolitan Government Building

A meteoric J-pop duo with a huge global following has pitched in to boost the world’s largest projection mapping show and help illuminate midsummer nights in Tokyo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808176674/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

YOASOBI / Butai ni Tatte (Standing on the Stage) (Photo: Business Wire)

An artwork, combining YOASOBI’s up-tempo vocal and instrumental music with a riot of images and colors, made its debut on the TOKYO Night & Light program on July 26. The nightly show uses the exterior of the 243-meter-tall Tokyo Metropolitan Government (TMG) No. 1 Building as its screen. Three other projections created by internationally acclaimed artists also joined the menu over the same weekend.

YOASOBI – female vocalist Ikura, 23, and male singer-songwriter Ayase, 30 - has contributed the newly composed “Butai ni Tatte (Standing on the Stage),” which echoes the emotions of athletes ready for competition. The song has been adopted by Japan’s public broadcasting corporation NHK as a theme song for its sports programs, and its first Night & Light presentation was timed to coincide with the Paris Olympics opening ceremony.

For the first screening, a horde of people gathered at the Citizens’ Plaza at the foot of the 48-story building, a landmark in the business and entertainment hub of Shinjuku. They watched animated silhouette images of runners and other athletes romp around on the wall.

The Night & Light project has lived up to the TMG’s goal of creating a “new tourism resource to color Tokyo’s nightlife,” attracting 280,000 visitors in five months since its launch on February 25. Projected onto an area, 127 meters by 110 meters, the show has been certified by Guinness World Records™ as the “largest architectural projection-mapped display (permanent).”

Screened every half an hour between 7:30 p.m. and 9:30 p.m. at present, the program strings together a few projections for 15 minutes. On weekends and holidays, the series feature crowd pullers such as the world-famous Japanese movie monster Godzilla and a work inspired by traditional Japanese Ukiyo-e paintings. “Standing on the Stage,” 3.5 minutes long, is to be screened every night for the time being.

Meaning a “night out,” YOASOBI is a global household name five years after its debut. Its hit “Idol,” the theme tune for the TV animation “Oshi no Ko,” became the first Japanese song to top Billboard’s Global (excluding U.S.) chart in June last year. It was also acknowledged as Japan’s best popular song in terms of royalties in the year to March 2024.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808176674/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye